

Nobivac Lepto

Authorised

- *Leptospira interrogans*, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain Ic-02-001, Inactivated
- *Leptospira interrogans*, serogroup Canicola, serovar Portland-vero, strain Ca-12-000, Inactivated

Product identification

Medicine name:

NOBIVAC LEPTO ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ
Nobivac Lepto

Active substance:

Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain Ic-02-001, Inactivated

Leptospira interrogans, serogroup Canicola, serovar Portland-vero, strain Ca-12-000, Inactivated

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain Ic-02-001, Inactivated

699.00 unit(s) / 1.00 Dose

Leptospira interrogans, serogroup Canicola, serovar Portland-vero, strain Ca-12-000,
Inactivated

990.00 unit(s) / 1.00 Dose

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

- Dog
-

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AB01

Legal status of supply:

This information is not available for this product.

Authorisation status:

Valid

Authorised in:

Greece

Package description:

Plastic box containing 50 type I glass vials of 1 ml (1 dose) closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap

Plastic box containing 10 type I glass vials of 1 ml (1 dose) closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap

Cardboard box containing 50 type I glass vials of 1 ml (1 dose) closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap

Cardboard box containing 10 type I glass vials of 1 ml (1 dose) closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Legal basis not covered by Directive 2001/82/EC

Marketing authorisation holder:

Intervet Hellas A.E.

Marketing authorisation date:

28/07/2003

Manufacturing sites for batch release:

INTERVET INTERNATIONAL B.V.

Responsible authority:

National Organization For Medicines

Authorisation number:

56940/08-09-2008/K-0148301

Date of authorisation status change:

8/09/2008

Reference member state:

Netherlands

Procedure number:

NL/V/0108/001

Concerned member states:

Belgium Denmark Greece Luxembourg Portugal Spain

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Source URL: <https://medicines.health.europa.eu/veterinary/600000037719>